1 min ago
Nektar Therapeutics Has More To Give
Investors should know within a month whether the FDA will approve Movantik, Nektar's opioid-induced constipation drug partnered with AstraZeneca that has $1B+ potential.
4 hrs ago
Pfizer Inc. Eyes Possible Actavis Bid Whilst Weighing Next Steps Over AstraZeneca PLC
Pfizer Inc. isn't giving up on striking an overseas takeover to cut its tax rate and gain a new pipeline of drugs, even as the potential cost of acquiring AstraZeneca Plc rises.
8 hrs ago
Astrazeneca Announces Partnership with Illumina to Develop Next...
In the first instance, intends to apply Illumina's cutting-edge technology to a novel companion diagnostic test in pivotal studies for one of its investigational oncology compounds.
12 hrs ago
London close: Astrazeneca leads FTSE higher on bid speculation
Increased speculation regarding ECB action, on the heels of weaker than forecast readings on the Eurozone economy, were offset by a weak report on UK retail sales.
15 hrs ago
Why AstraZeneca (AZN) Stock Is Higher Today
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
18 hrs ago
AstraZeneca plc Receives "Hold" Rating from Beaufort Securities
AstraZeneca plc opened at 4375.50 on Thursday. AstraZeneca plc has a 52 week low of GBX 3086.50 and a 52 week high of GBX 5750.00.
22 hrs ago
Customer Interaction Solutions
Illumina Announces Strategic Partnerships with AstraZeneca, Janssen...
The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine.
Wed Aug 20, 2014
AstraZeneca PLC, Mitsubishi Tanabe Pharma Corporation Link Up For Diabetes Research
AstraZeneca and Mitsubishi Tanabe Pharma said on Wednesday they said signed a three-year research collaboration into diabetic nephropathy, or kidney failure due to diabetes.
Customer Interaction Solutions
Clinigen Group Further Strengthens Oncology Support Portfolio with...
Clinigen Group plc the specialty global pharmaceutical company today announces the acquisition of the global rights to the oncology support therapy, Ethyol from AstraZeneca.
Tue Aug 19, 2014
The Zacks Analyst Blog Highlights: Tesla Motors, CarMax,...
Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
The Negative Impact Of Pfizer's Mergers And Budget Cuts On Cancer R&D
"And then, I don't know if Mikael Dolsten is on the call, but just a question on business development, analyzing, outlicensing activity.
How Will AstraZeneca (AZN) Stock Respond To U.S. Clearing Heart Drug Trial?
The company said the government was closing its investigation into the 18,000-patient study and no further action was planned.
Mon Aug 18, 2014
Us Doj Closes Investigation into Plato
UNITED STATES DEPARTMENT OF JUSTICE CLOSES INVESTIGATION INTO PLATO CLINICAL TRIAL FOR BRILINTA AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with Brilinta .
Recent Analysts' Ratings Updates for AstraZeneca plc
A number of stock research firms have changed their ratings and price targets for AstraZeneca plc during the last seven days: AstraZeneca plc had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co..
Sun Aug 17, 2014
2nd Half Of 2014 Biotechnology Catalysts--Part 4
Through knowing when PDUFA decisions are going to be made, investors can benefit from the increased momentum and share price heading into the decision.
Thu Aug 14, 2014
Why GlaxoSmithKline Is A Tempting Buy
By now, most investors know all the problems facing pharmaceutical giant GlaxoSmithKline .
AstraZeneca PLC Starts Late-Stage Asthma Drug Trial
Astrazeneca Advances Tralokinumab To Phase III In Severe Asthma Thursday, 14 August 2014: AstraZeneca today announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company's global biologics research and development arm.
Wed Aug 13, 2014
Dynavax Is More Than Just HEPLISAV
Successful Phase 1 study of AZD1419 seemed to be a side note; yet AZD1419 may be the forgotten catalyst for Dynavax over the next year.
Wall Street Journal
AstraZeneca Gets Good Results From Gout Drug Trials
AstraZeneca PLC reported on Wednesday positive results from three combination Phase III clinical trials of treatments for patients with gout, an inflammatory arthritis.
Mon Aug 11, 2014
For Lexicon Pharmaceuticals, No News Remains Bad News
Lexicon updates investors on its second quarter results, but still has no partner to develop LX4211 in Type 2 diabetes.